Moderna Inc (NASDAQ: MRNA) has lost the bid to invalidate a key patent related to the development of several of its next-generation vaccines, including one meant for coronavirus, to Arbutus Biopharma Corp (NASDAQ: ABUS), Reuters reported.What Happened The Massachusetts-headquartered company’s contention that the ‘069 patent, related to the technology for delivering mRNA vaccines, owned by Arbutus described obvious concepts was rejected by an administrative court under the United States Patent and Trademark Office on Thursday.The patent is supposedly related to lipid nanoparticle (LNP) technology, which helps the human body create its own therapeutic proteins.A patent lawyer, Zachary Silbersher, told Reuters …read more
Source:: Yahoo Finance
